The policy was associated with an increase in the probability of receiving an immediate postpartum LARC overall
Absolute 5.6–percentage point increase (95% CI, 3.7 to 7.4)
There were significantly larger effects for non-Hispanic Black individuals than non-Hispanic White individuals
Difference in coefficients 3.54 (95% CI, 1.35 to 5.73); P=0.002
The policy was associated with a decrease in the probability of
Subsequent preterm birth
0.4 percentage point decrease (95% CI, −0.7 to −0.1)
0.3 percentage point decrease (95% CI, −0.7 to 0)
Above differences for preterm and LBW births did not differ between non-Hispanic Black and non-Hispanic White individuals
Among non-Hispanic Black individuals, the policy was associated with
A decrease in the probability of short-interval birth
0.6–percentage point decrease (95% CI, −1.2 to −0.1)
An increase in days to next birth
27-day increase (95% CI, 11 to 44)
Policies that increase access to postpartum LARC among low-income individuals are associated with improved infant outcomes
However, policies should address inequities
The authors state
While our findings support the role of increased access to highly effective forms of postpartum contraception in improving birth outcomes, it is imperative that efforts to expand access focus on assuring comprehensive access to all forms of contraception without coercion
Additional policy solutions are needed to improve infant health, including those that directly address structural and interpersonal racism to reduce racial disparities in infant health
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan